Page 64 - Haematologica June

966
M. Krevvata et al.
aspiration. No significant improvement was observed asso- ciated with the presence of human MSC in the murine environment. Interestingly, in the majority of cases in which MSC appeared to have a slightly positive effect in engraftment levels on week 8 after transplantation, the effect was lost when engraftment levels were reassessed at week 16 (data not shown). In a direct comparison experiment
A
between NSG and NSG-S mice, the presence of MSC pro- duced a mild improvement in the engraftment levels in the patients’ samples tested, at eight weeks, irrespective of the mouse strain. Similarly to before, the positive effect appeared to fade at 16 weeks in both NSG and NSG-S mice (Online Supplementary Figure S1). Next, to assess whether MSC from various sources might contribute to MDS
B
C
DEF
Figure 3. Myelodysplastic syndromes (MDS) cells engraft in NSG-S mice. (A) Schematic representation of experimental set up. Patient-derived bone marrow mononuclear cells (MNC) alone or in combination with mesenchymal stem cells (MSC) were intrafemorally injected in NSG-S mice. Characteristic gating strategy for analyzing the (B) myeloid (CD33), lymphoid (CD19, CD3), progenitor (CD45RA, CD123, CD38) and (C) erythroid (GlyA) subpopulations found in the bone marrow of mice engrafted with patients’ bone marrow MNC samples. Immunostainings of (D) hCD33, (E) glycophorin C and (F) GPIIIa of decalcified bone marrow sections from sternums of mice engraft- ed with human MDS.
haematologica | 2018; 103(6)